NATURALIFE
LIVE

Serial Number

79289279

Owner

Overture Life, Inc

Attorney

Lindy M. Herman

Filing Date

Jun 9, 2020

Add to watchlist:

No watchlists yet
View on USPTO

NATURALIFE Trademark

Serial Number: 79289279 • Registration: 7232401

NATURALIFE is a trademark filed by Overture Life, Inc on June 9, 2020. The trademark is classified under Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Overture Life, Inc (8 trademarks)

50 South Pointe Drive

Entity Type: 03

Trademark Details

Filing Date

June 9, 2020

Registration Date

December 5, 2023

Published for Opposition

September 19, 2023

Goods & Services

Apparatus for scientific and laboratory research, namely, incubators; laboratory apparatus and instruments, namely, microfluidic biochips for gamete denudation, fertilization, embryo development and image capture, for research and scientific purposes; scientific instruments, namely, electronic analyzers for testing and analyzing chemical and biological substances for the presence, absence, or quantity of biologics

In vitro fertilization services; medical services, specifically, in-vitro fertilization; analysis of human tissues for medical treatment; medical analysis for the diagnosis and treatment of people; medical consultancy in the field of pregnancy; medical assistance; medical care; medical consultations; gynecological cytology services; medical examination for persons; medical information; medical analysis services for diagnostic and treatment purposes; medical and healthcare services related to DNA, genetics and genetic testing; sperm bank services; human fertility treatment services; pregnancy testing services

Instruments for medical analysis relating to the treatment of persons, namely, mass spectrometers for analyzing biomarkers and identifying metabolomics profiling, genetic blueprint, aneuploidy screening, genetic abnormalities screening and for pregnancy and miscarriage likelihood screening; medical diagnostic apparatus for detecting embryo DNA, metabolites, proteins, morphological quality assessment of cleavage stage embryos and blastocysts for pregnancy and miscarriage likelihood; medical diagnostic apparatus for diagnosis, examination and monitoring embryos; medical diagnostic apparatus for tracking embryo development; medical diagnostic apparatus for embryo image assessment, specifically for analyzing microscopy images of developing embryos and medical imaging apparatus for diagnosing medical conditions during the process of in-vitro fertilization and incorporating recorded operating system software

Design and testing of new products for others; design and testing for new product development; scientific and technological services, namely, scientific research; product development in the field of assisted reproductive technologies; design and development of products in the field of embryology, assisted reproductive technologies research; development of new products; scientific research and development; development of medical testing methods; product development analysis; product development evaluation; research and development of new products; design and development of medical technology; biological research; clinical research in the field of in vitro fertilization, clinical reproduction and medical diagnostics; medical research; scientific research with a medical purpose; research and development in the field of pharmacy and biotechnology; development and design of new products; scientific and technological design in the field of assisted reproductive technologies; specialized machinery design; design of new products; new product design; scientific research and design in the field of in vitro fertilization, automatic time-lapse incubators, microscopes, micromanipulators, embryo culture, labware, and gamete processing methods; research relating to design in the field of assisted reproductive technologies; medical research relating to human tissue; medical and scientific research, namely, conducting clinical trials for others; clinical studies being clinical research in the field of in Vitro Fertilization, embryology, clinical reproduction, fertility and infertility services and medical diagnostic; clinical research in the field of tissue engineering of artificial placenta; artificial endometrium research in the field of pharmacogenetics; medical research; medical laboratory services; biomedical research services; technological analysis and evaluation of products during product development to determine efficacy and conformity with certification standards; computer aided design of molds

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 26, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 5, 2024 FICS
FINAL DISPOSITION PROCESSED
Mar 5, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 5, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 5, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 5, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 19, 2023 NPUB
PUBLISHED FOR OPPOSITION
Sep 19, 2023 PUBO
NOTIFICATION PROCESSED BY IB
Sep 17, 2023 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 30, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 30, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 30, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 16, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 12, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 12, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 12, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 12, 2023 CNEA
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Jan 20, 2023 GNS1
SUBSEQUENT FINAL EMAILED
Jan 20, 2023 GNSF
SUBSEQUENT FINAL REFUSAL WRITTEN
Jan 20, 2023 CFRC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Nov 21, 2022 RCCK
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Nov 8, 2022 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 12, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 12, 2022 GNSL
SUSPENSION LETTER WRITTEN
Apr 12, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 23, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 22, 2022 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 22, 2022 ERFR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 1, 2022 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 15, 2021 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 15, 2021 OPNR
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 20, 2021 GNFN
FINAL REFUSAL E-MAILED
Aug 20, 2021 GNFR
FINAL REFUSAL WRITTEN
Aug 20, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 14, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 13, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 13, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 13, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jan 13, 2021 GNRT
NON-FINAL ACTION WRITTEN
Jan 13, 2021 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 3, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 2, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 2, 2020 TROA
REFUSAL PROCESSED BY IB
Oct 25, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 8, 2020 RFCS
REFUSAL PROCESSED BY MPU
Oct 8, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 20, 2020 RFCR
NON-FINAL ACTION WRITTEN
Sep 19, 2020 CNRT
NEW REPRESENTATIVE AT IB RECEIVED
Sep 18, 2020 NREP
ASSIGNED TO EXAMINER
Sep 10, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 14, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 10, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 9, 2020 REPR